Who Makes Mounjaro, and How Does It Reach UK Patients?

The misconception: Mounjaro is just another GLP-1

The most common misunderstanding about Mounjaro is that it works the same way as Wegovy or Ozempic, that it is essentially a branded version of semaglutide with a different label. It is not. Tirzepatide, the molecule Eli Lilly developed, activates two separate gut-hormone receptors: the GLP-1 receptor and the GIP receptor. Semaglutide activates only GLP-1. That distinction (a dual agonist versus a single one) is what makes tirzepatide pharmacologically different, and it is why regulators, NICE, and clinicians treat them as separate medicines rather than interchangeable alternatives.

Lilly spent years in clinical development establishing this difference. The SURMOUNT programme, which studied tirzepatide specifically in adults with obesity rather than diabetes, ran across multiple trials involving thousands of participants. SURMOUNT-1 alone randomised 2,539 adults and reported average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, as published in the New England Journal of Medicine. Those results shaped the NICE recommendation that followed. Getting the mechanism right matters, because it shapes everything downstream: dosing, side-effect profile, and who the medicine is suitable for.

So while Mounjaro sits in the same broad class of injectable weight-loss medicines, it is a distinct product with its own clinical evidence base, and if you are curious about who makes Mounjaro as a weight-loss treatment, the answer points to a manufacturer with a specific manufacturing and supply infrastructure.

Lilly's role in the UK supply chain

Eli Lilly holds the UK marketing authorisation for Mounjaro, which is granted and overseen by the MHRA. That authorisation covers both the weight management and type 2 diabetes indications. Lilly manufactures tirzepatide and supplies it to the UK through an authorised pharmaceutical distribution network, the same regulated supply chain used by NHS pharmacies, hospital trusts, and GPhC-registered online pharmacies.

This point matters more than it might seem. A genuine Mounjaro KwikPen comes from Lilly's authorised supply, arrives in licensed wholesale channels, and is dispensed by a registered pharmacy against a valid prescription. It does not come through a social media seller, a grey-market importer, or a website that sidesteps clinical checks. The MHRA has warned publicly about counterfeit and illegally traded weight-loss pens, and in 2025 enforcement operations seized approximately 20 million doses with a street value of around £45 million, including the first illicit UK manufacturing site producing counterfeit tirzepatide pens. The warning is clear and the MHRA's Yellow Card scheme allows anyone to report a suspect seller.

At nume, our pharmacy sources Mounjaro through Eli Lilly's authorised UK supply. That is not a marketing statement, it is a supply-chain requirement for any GPhC-registered pharmacy. You can verify our GPhC registration (9012878) on the pharmacy regulator's register.

What Lilly's UK licence actually covers

Understanding what Lilly is licensed to sell matters for patients trying to make sense of the options available to them. In the UK, Mounjaro carries a licence for two purposes: weight management in adults, and the treatment of type 2 diabetes. The weight-management licence applies to adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition. Eligibility details and the full clinical picture are set out on the NICE appraisal of tirzepatide (TA1026), which recommended Mounjaro for use in England.

Lilly also holds a licence for Mounjaro in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15mg. The treatment starts at the lowest strength for tolerability reasons and is titrated by a prescriber, typically in four-week steps, up to the dose that works best for that individual. The prescriber decides the pace and the ceiling, not the patient and not the manufacturer. Lilly sets what is licensed; the prescriber decides what is appropriate. Those are different decisions.

One practical detail worth knowing: Mounjaro is dispensed as a pre-filled KwikPen. Each pen contains four doses, a month's supply in a single device. When your pen arrives at home via DPD, tracked to your door in plain packaging, it goes straight into the fridge. The pen itself is compact, discreet, and designed for self-injection once a week. Lilly engineered the delivery system as part of the product; the pen format is not incidental.

If you want to explore whether Mounjaro is right for your situation, the place to start is a clinical consultation, where a prescriber reviews your full health picture.

Eli Lilly's broader track record and why it is relevant

Lilly is not a newcomer to endocrinology or metabolic medicine. The company has manufactured insulin for over a century and has been active in diabetes research for decades. Tirzepatide is an extension of that research lineage, a molecule that emerged from Lilly's work on gut hormones and their role in blood-sugar regulation and appetite, and patients who want to understand who made Mounjaro will find that background informs both the scientific rationale for the medicine and the manufacturing quality standards behind it.

For patients weighing up whether to pursue treatment, understanding the manufacturer's standing is reasonable due diligence. Mounjaro is not a compound, not a generic, and not a product from an unverified source. It is a branded, MHRA-authorised medicine produced by a major pharmaceutical company with an established UK presence, available only through the licensed supply chain and dispensed only on prescription. That chain of custody (from Lilly's production facility to a registered pharmacy to the patient) is what legitimate treatment looks like. Our clinical team at nume works within that chain, and our prescribers review every consultation personally before anything is dispensed.

If you have questions about what Mounjaro costs through a private pharmacy, or about who Mounjaro is suitable for and how the clinical assessment works, our FAQs cover both in detail. Ready to take the next step? Start your free consultation and a prescriber will review your case the same day.